Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P09619
UPID:
PGFRB_HUMAN
Alternative names:
Beta platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; CD140 antigen-like family member B; Platelet-derived growth factor receptor 1
Alternative UPACC:
P09619; B5A957; Q8N5L4
Background:
Platelet-derived growth factor receptor beta (PDGFRB) plays a pivotal role in embryonic development, cell proliferation, differentiation, and migration. It is crucial for blood vessel development and the recruitment of pericytes and smooth muscle cells, facilitating the formation of a branched network of capillaries in various organs.
Therapeutic significance:
PDGFRB's involvement in diseases such as Myeloproliferative disorder chronic with eosinophilia, Acute myelogenous leukemia, and others, highlights its potential as a target for therapeutic intervention. Understanding PDGFRB's role could pave the way for novel treatments for these malignancies.